The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Total revenues | 2,797 |
| Research and development-Legacy Selecta Programs | 0 |
| Research and development-Descartes08For MG | 22,893 |
| Research and development-Early Stage Programs | 5,795 |
| Research and development-Research And Development Employee Expenses | 16,826 |
| Research and development-Research And Development Share Based Payment Arrangement Expense | 4,772 |
| Research and development-Research And Development Facilities And Other Expenses | 7,748 |
| General and administrative | 31,468 |
| Impairment of indefinite-lived intangible and long-lived assets | 56,700 |
| Other (income) expense, net | 13,103 |
| Net loss | -130,302 |
| Depreciation and amortization | 2,959 |
| Noncash lease expense | 778 |
| Loss on disposal of property and equipment | 0 |
| Impairment of indefinite-lived intangible and long-lived assets | 56,700 |
| Stockbased compensation expense | 10,521 |
| Gain on change in fair value of warrant liabilities | -3,695 |
| Loss on change in fair value of cvr liability | 4,354 |
| Loss on change in fair value of forward contract liabilities | 0 |
| Loss on impairment of investment | 2,000 |
| (benefit) provision for deferred taxes | -9,193 |
| Accounts receivable | 243 |
| Unbilled receivable | 0 |
| Prepaid expenses and other assets | 5,298 |
| Accounts payable | 1,066 |
| Deferred revenue | 0 |
| Accrued expenses and other liabilities | -3,588 |
| Net cash used in operating activities | -73,941 |
| Purchases of property and equipment | 5,454 |
| Proceeds from the sale of property and equipment | 0 |
| Net cash used in investing activities | -5,454 |
| Proceeds from issuance of series a preferred stock, gross in private placement | 0 |
| Net proceeds from issuance of common stock and series b preferred stock in private placement | 0 |
| Equity offering costs | 624 |
| Proceeds from exercise of common warrants | 0 |
| Proceeds from exercise of stock options | 323 |
| Distribution of contingent value rights | 7,754 |
| Net cash (used in) provided by financing activities | -8,055 |
| Effect of exchange rate changes on cash | 45 |
| Net change in cash, cash equivalents, and restricted cash | -87,405 |
| Cash and cash equivalents at beginning of period | 214,279 |
| Cash and cash equivalents at end of period | 126,874 |
Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. (RNAC)